{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-012488","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2026-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.785399+00:00","generated_at":"2026-05-15T05:47:34.787423+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eton Pharmaceuticals appoints Judith Matthews as CFO effective June 1, 2026","bullets":["Judith Matthews will become CFO on June 1, 2026, succeeding James Gruber who remains through May 31 then six-month consulting.","Annual base salary of $440,000, target bonus 45% of salary, one-time option for 37,000 shares vesting over 4 years.","Matthews was previously CFO of Iterum Therapeutics (2015-2026) and VP Finance at Durata Therapeutics.","Gruber to provide transition support via six-month consulting agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-012488","json":"https://secwatch.observer/filing/0001437749-26-012488.json","markdown":"https://secwatch.observer/filing/0001437749-26-012488.md","text":"https://secwatch.observer/filing/0001437749-26-012488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926012488/0001437749-26-012488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926012488/eton20260413_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:47:34.787423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}